Overview
- Baron Capital published its Q2 2026 investor letter in early August and reported the Baron Health Care Fund rose 11.99% in the quarter while noting strong stock selection in biotech, devices and diagnostics.
- The fund added to beaten-down positions such as Mettler-Toledo and re-established stakes in managed-care names including Elevance and UnitedHealth based on what it sees as attractive valuations and improving margin prospects.
- Baron flagged company-level near-term catalysts it believes will drive upside, including Veradermics’ Phase 3 hair-loss readouts expected in the second half of 2026 and Edwards’ updated Medicare coverage for TAVR that could lift procedure volumes.
- The letter highlighted commercial and clinical launches that need careful monitoring, noting Insmed’s Brinsupri launch has shown early sales but investor concern over treatment discontinuations and Gilead’s Yeztugo faces conservative near-term guidance despite long-term promise.
- Baron emphasized diagnostics and precision medicine winners such as BillionToOne, which reported strong Q1 revenue growth and broader commercial insurance coverage for its UNITY prenatal test, and said AI could materially cut managed-care administrative costs as margins recover.